Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, ITUS Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Building Materials while trimming auto and banking exposures."
In 2024, ITUS Capital returned 12.76% vs 10.09% for the benchmark, bringing its since-inception return to 320%. The fund manager highlights a structural transition in Indian equities driven by resilient domestic inflows, making the market less cyclical. Top contributing sectors for 2024 were Healthcare and Construction/Realty (exited), while Banks and IT underperformed. For CY25, the fund plans to increase concentration in top holdings, target 25-30 names to decrease the tail, and monitor macro risks like rebounding inflation. Sector-wise, the fund is heavily overweight on Healthcare (Pharma and Hospitals) and Building Materials, while remaining underweight on Banks, IT, and FMCG.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Growth Outlook
Market outlook remains above average conviction: ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Risk Appetite
Risk appetite posture is above average conviction: ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Forward Guidance
Forward guidance signal: ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Language Signal
Tone analysis indicates above average conviction language: ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
Time Horizon
Investment time horizon reflects a high conviction orientation. ITUS Capital posted a strong 12.76% return in 2024. Entering CY25, the fund is increasing concentration to 25-30 high-conviction names, remaining overweight on Healthcare and Build...
